SynthesisDigestive diseases and sciences2026
Comparative Outcomes of Primary Sclerosing Cholangitis With and Without Comorbid Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Synthesis in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease frequently associated with inflammatory bowel disease (IBD). While PSC with IBD is recognized as a distinct entity, comparative outcomes of PSC with IBD versus PSC alone remain uncertain. This systematic review and meta-analysis aimed to compare clinical outcomes in patients with PSC with and without comorbid IBD.
methodsWe conducted a systematic review and meta-analysis following PRISMA and MOOSE guidelines. MEDLINE, PubMed, Embase, Scopus, and CENTRAL were searched to October 2025. Eligible studies included adults with PSC stratified by IBD status, reporting risk of all-cause mortality or liver transplant, malignancy, graft survival, or recurrent PSC. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models.
resultsTwenty-six studies involving 23,837 patients (16,502 PSC-IBD; 7,335 PSC only) were included. PSC-IBD was associated with a significant decrease in all-cause mortality or liver transplantation compared with PSC alone (HR 0.77, 95% CI, 0.62-0.97). Subgroup analysis showed that both PSC with Crohn's disease (HR 0.67, 95% CI 0.54-0.84) or ulcerative colitis (HR 0.72, 95% CI 0.55-0.95) had a significantly lower risk of all-cause mortality or liver transplantation compared to PSC alone. Indeterminate colitis carried a higher risk compared with Crohn's disease (HR 1.57, 95% CI 1.00-2.4). PSC-IBD was associated with increased risk of hepatopancreatobiliary cancer (HR 2.37, 95% CI 1.35-4.15). There was no significant difference in risk of recurrent PSC between PSC-IBD and PSC only.
conclusionPSC-IBD may be associated with a lower risk of all-cause mortality and liver transplant compared to PSC alone, although these findings should be interpreted cautiously given the limited number of studies for several outcomes. Further prospective studies are needed to refine risk stratification.
Indexed as
Identifiers
42084721What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.